Anonymous ID: f0366d May 8, 2026, 3:14 p.m. No.24585268   🗄️.is 🔗kun   >>5288 >>5315 >>5487 >>5675 >>5741

Why Ivermectin and Hydroxychloroquine Could Work for Hantavirus

As the WHO downplays ivermectin for hantavirus, the underlying science and preclinical data tell a very different story.

 

Ivermectin’s Strong Track Record Against RNA Viruses

Since the early 2010s, researchers have documented ivermectin’s broad-spectrum antiviral activity against a wide range of RNA viruses, including dengue, Zika, West Nile, yellow fever, chikungunya, influenza, HIV, and SARS-CoV-2. These antiviral effects are summarized across dozens of studies in a 2020 systematic review by Heidary et al.

The most compelling real-world evidence comes from its performance against COVID-19. The comprehensive real-time meta-analysis at https://c19early.org/i now includes 106 studies involving hundreds of thousands of patients. These studies consistently show strong benefits — particularly when used early or as prevention — with major reductions in mortality, hospitalization, and severe disease.

 

https://www.thefocalpoints.com/p/why-ivermectin-and-hydroxychloroquine

Anonymous ID: f0366d May 8, 2026, 3:19 p.m. No.24585288   🗄️.is 🔗kun   >>5487 >>5675 >>5741

>>24585268

Crucially, hantaviruses are also RNA viruses — specifically negative-sense single-stranded RNA viruses. While they differ in structure and replication details from viruses like SARS-CoV-2, they still rely on host cell machinery and intracellular transport pathways that ivermectin is known to disrupt.

 

Mechanistically, ivermectin inhibits importin α/β nuclear transport, a pathway many RNA viruses exploit to shuttle viral proteins into the host cell nucleus to suppress antiviral responses. Hantavirus nucleocapsid (N) protein has been shown to interact with these same host pathways to interfere with immune signaling. By blocking this transport system, ivermectin may prevent the virus from disabling the host’s innate defenses.

 

In addition, ivermectin interferes with viral replication and assembly processes inside the cell, and exerts anti-inflammatory effects that could blunt the vascular leakage and lung injury characteristic of severe hantavirus disease.

 

This is the key point: ivermectin does not need to be “hantavirus-specific” to be effective. Its antiviral activity is largely host-directed — targeting conserved cellular mechanisms that many RNA viruses, including hantaviruses, depend on.

 

Given this combination — a shared RNA-virus biology, overlapping reliance on host pathways, and a well-documented antiviral mechanism — ivermectin likely exerts at least some degree of anti-hantavirus activity and warrants serious investigation, not dismissal.